Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28851899 | 0.82 | CYP1A2 (0.48) | CYP1A2ALDH1A1SMN1; SMN2HTR3APLA2G7 | |
| SCHEMBL28110411 | 0.80 | CYP1A2 (0.56) | CYP1A2ALDH1A1MAPTTP53NPC1 | |
| SCHEMBL15668542 | 0.76 | CYP1A2 (0.62) | CYP1A2ALDH1A1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL15668407 | 0.75 | NPC1 (0.56) | CYP1A2ALDH1A1SMN1; SMN2HTR3APLA2G7 | |
| SCHEMBL4904960 | 0.74 | NPC1 (0.56) | ALDH1A1SMN1; SMN2PLA2G7MAPTTP53 | |
| SCHEMBL5188049 | 0.74 | CYP1A2 (0.63) | CYP1A2ALDH1A1SMN1; SMN2HTR3AMAPT | |
| SCHEMBL11032029 | 0.74 | CYP1A2 (0.56) | CYP1A2ALDH1A1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL28227419 | 0.73 | CYP1A2 (0.54) | CYP1A2SMN1; SMN2MAPTTP53NPC1 | |
| SCHEMBL22720144 | 0.73 | CYP1A2 (0.48) | CYP1A2ALDH1A1SMN1; SMN2MAPTTP53 | |
| SCHEMBL30527184 | 0.72 | CYP1A2 (0.60) | CYP1A2ALDH1A1SMN1; SMN2HTR3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-2914253-B1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANTBIOSCIENCE INC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| EP-2914253-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | Nant Holdings IP, LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014071298-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014071298-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | SMO, SHH, SOS1 | CYP1A2 4726/4885ALDH1A1 2719/4885SMN1; SMN2 3644/4885 |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | SMO, SHH, SOS1 | CYP1A2 4726/4885ALDH1A1 2719/4885SMN1; SMN2 3644/4885 |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | SMO, SHH, SOS1 | CYP1A2 4726/4885ALDH1A1 2719/4885SMN1; SMN2 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.